|
@
genentech
USA
|
|
Official Twitter Site for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
|
|
|
6.739
Tweetovi
|
244
Pratim
|
108.034
Osobe koje vas prate
|
| Tweetovi |
|
Genentech
@genentech
|
20 h |
|
#DYK studying the humble fruit fly could help advance regenerative medicine? Grab some earbuds to learn more in the final #podcast episode of Season 3, where Heinrich Jasper explains how his research could aid in extending health. bit.ly/36ZfYB4
|
||
|
|
||
|
Genentech
@genentech
|
4. velj |
|
Thanks for everything you do to support the #pulmonaryfibrosis community! We’re excited to join you in NYC later this month. twitter.com/PFFORG/status/…
|
||
|
|
||
|
Genentech
@genentech
|
31. sij |
|
We were named one of the @BestWorkplaces for Commuters! One of our 2020 sustainability goals is to reduce CO2 emissions from transportation activities by 10%. Learn more about our efforts to create an environmentally sustainable future: bit.ly/2OelwAT #BWC2020 pic.twitter.com/mZE8zas2uJ
|
||
|
|
||
|
Genentech
@genentech
|
28. sij |
|
This National #MentoringMonth, learn how more than 1,300 of our employees volunteer their time as mentors to inspire the next generation of scientists, innovators and critical thinkers. bit.ly/2t4Qa8B pic.twitter.com/QGTHj6Ykad
|
||
|
|
||
|
Genentech
@genentech
|
28. sij |
|
Check out our new study in @CellReports from Jason Hackney and colleagues which identifies causal genes for age-related macular degeneration, a leading cause of vision loss. bit.ly/310awMV
|
||
|
|
||
|
Genentech
@genentech
|
28. sij |
|
ICYMI: The @US_FDA is reviewing our #immunotherapy combination for the most common type of #livercancer under its Real-Time Oncology Review pilot program. Learn more: bit.ly/37DvgfK
|
||
|
|
||
|
Genentech
@genentech
|
27. sij |
|
We're proud to help support this important research initiative around #healthequity in clinical trials with our partner @SU2C! #advancinginclusiveresearch twitter.com/SU2Cscience/st…
|
||
|
|
||
|
Genentech
@genentech
|
27. sij |
|
Is it possible to extend human health? Check out the final #podcast episode of Season 3 to learn how we might be able to engage our body's own repair mechanisms to delay the onset of age-related disease. bit.ly/37v4ypC
|
||
|
|
||
|
Genentech
@genentech
|
27. sij |
|
#Breaking: Our #immunotherapy combination for the most common type of #livercancer is being reviewed under the @US_FDA Real-Time Oncology Review pilot program, which aims to get treatments to patients faster. gene.com/media/press-re…
|
||
|
|
||
|
Genentech
@genentech
|
24. sij |
|
Today we shared an update on our Phase III study evaluating our immunotherapy for a specific type of bladder cancer. Learn more: gene.com/media/press-re…
|
||
|
|
||
|
Genentech
@genentech
|
23. sij |
|
#Breaking: Pivotal trial evaluating our spinal muscular atrophy (#SMA) medicine meets primary endpoint in infants with Type 1 #SMA gene.com/media/press-re…
|
||
|
|
||
| Genentech proslijedio/la je tweet | ||
|
Adaptive Biotech
@AdaptiveBiotech
|
22. sij |
|
“We are going after multiple TCRs against multiple targets simultaneously...that’s why we’re excited about this strategy” - CSO Harlan Robins, with @genentech VP, Cancer Immunology, Ira Mellman at #PMWC20 Learn more about our partnership: rebrand.ly/xr7dp3 pic.twitter.com/HBrqXckCtR
|
||
|
|
||
| Genentech proslijedio/la je tweet | ||
|
JExpMed
@JExpMed
|
21. sij |
|
Cancer mutations create neoantigens that are of great interest for immunotherapy, but their accurate identification remains a challenge. @genentech researchers show that mutation position is an important determinant for immunogenicity bit.ly/2Nwtd5l @jamescev19 @jsuchit pic.twitter.com/WAS3l1m3Ew
|
||
|
|
||
| Genentech proslijedio/la je tweet | ||
|
Adaptive Biotech
@AdaptiveBiotech
|
21. sij |
|
Join co-founder & Chief Scientific Officer, Harlan Robins, and @genentech Vice President, Cancer Immunology, Ira Mellman at #PMWC20 for a fireside chat on progress, challenges, and what’s next for cancer immunotherapy. Read more about our partnership: rebrand.ly/xr7dp3 pic.twitter.com/ExPsWpLzm2
|
||
|
|
||
|
Genentech
@genentech
|
21. sij |
|
Tomorrow at #PMWC20, Ira Mellman, Vice President, Cancer Immunology, joins @AdaptiveBiotech Co-founder & Chief Scientific Officer, Harlan Robins, for a fireside chat on cancer immunotherapy. Read more about our partnership with Adaptive. bit.ly/37fqoxr
|
||
|
|
||
|
Genentech
@genentech
|
21. sij |
|
We’re honored to be named one of @Forbes Best Employers for Diversity! Learn how we’re fostering a culture where difference is valued and celebrated: bit.ly/2TLvqO4 pic.twitter.com/CsCQYOUIfm
|
||
|
|
||
|
Genentech
@genentech
|
17. sij |
|
Neoantigens result from cancer-specific genetic mutations. In @JExpMed, a team led by Aude-Hélène Capietto, Suchit Jhunjhunwala & Lélia Delamarre identify traits of these mutations that could help prioritize targets for future cancer #immunotherapies. bit.ly/30wjsJF
|
||
|
|
||
|
Genentech
@genentech
|
17. sij |
|
Looking for in-flight entertainment on your way home from #JPM20? Tune in to our latest #podcast episode to hear from Mark Lee and David Shames about how #bigdata could help deliver personalized care to those who need it. bit.ly/2QYvisS
|
||
|
|
||
|
Genentech
@genentech
|
16. sij |
|
DYK that of the nearly 4,000 “druggable” targets known today, only about a quarter have been drugged or have a medicine that can impact them? See how we’re working to address this long-standing challenge with our partners. #JPM20 bit.ly/2TtNzjm
|
||
|
|
||
|
Genentech
@genentech
|
15. sij |
|
Solving the challenges facing the healthcare industry is best tackled as a team. That’s why we have 220 ongoing #collaborations around the world. Learn more about our continued commitment to #partnering. #JPM20 bit.ly/2QXkk75
|
||
|
|
||